IMR Press / FBL / Volume 27 / Issue 4 / DOI: 10.31083/j.fbl2704121
Open Access Review
CAR-T Cells Targeting Immune Checkpoint Pathway Players
Show Less
1 Promab Biotechnologies, Richmond, CA 94806, USA
*Correspondence: (Vita Golubovskaya)
Academic Editor: Graham Pawelec
Front. Biosci. (Landmark Ed) 2022, 27(4), 121;
Submitted: 26 January 2022 | Revised: 15 March 2022 | Accepted: 17 March 2022 | Published: 2 April 2022
(This article belongs to the Special Issue CAR-T Cell Therapy - Novel Approaches and Challenges)
Copyright: © 2022 The Author(s). Published by IMR Press.
This is an open access article under the CC BY 4.0 license.

CAR (Chimeric antigen receptor)-T cell therapy has become a very promising type of immunotherapy against hematological cancers. This report is focused on CAR-T cells targeting immune checkpoint proteins expressed on tumor cells. The CD70, CD47, CD80, CD86, B7H3, B7H4, PDL-1, TIGIT CAR-T cells and other CAR-T cells are discussed as an effective approach to deplete tumor cells expressing checkpoint proteins. CAR-T cell therapy targeting checkpoint pathways is a promising therapy to decrease inhibitory signaling pathways. The review highlights future directions and perspectives in CAR-T cells targeting immune checkpoint pathways.

CAR-T cell
Fig. 1.
Back to top